Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Tapan M. Kadia"'
Autor:
Nicholas J. Short, Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron, Courtney D. Dinardo, Naval Daver, Marina Konopleva, Gautam Borthakur, Elizabeth J. Shpall, Uday Popat, Richard E. Champlin, Rohtesh Mehta, Gheath Al-Atrash, Betul Oran, Elias Jabbour, Guillermo Garcia-Manero, Ghayas C. Issa, Guillermo Montalban-Bravo, Musa Yilmaz, Abhishek Maiti, Hagop Kantarjian
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-10 (2022)
Abstract Background Treated secondary acute myeloid leukemia (ts-AML)—i.e., AML arising from a previously treated antecedent hematologic disorder—is associated with very poor outcomes. The optimal frontline treatment regimen for these patients is
Externí odkaz:
https://doaj.org/article/98d8349f6793447b88974dcf1c4a8542
Autor:
Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia-Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S. Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Naval G. Daver
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020)
Abstract Background Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45–55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of patients treated were p
Externí odkaz:
https://doaj.org/article/7f93c4d49f714de3a3a0ebfafee5e7e2
Autor:
Musa Yilmaz, Mansour Alfayez, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Marina Y. Konopleva, Sanam Loghavi, Rashmi Kanagal-Shamanna, Keyur P. Patel, Elias J. Jabbour, Guillermo Garcia‑Manero, Naveen Pemmaraju, Sherry A. Pierce, Issa Ghayas, Nicholas J. Short, Guillermo Montalban-Bravo, Koichi Takahashi, Rita Assi, Ahmad S. Alotaibi, Maro Ohanian, Michael Andreeff, Jorge E. Cortes, Hagop M. Kantarjian, Farhad Ravandi, Naval G. Daver
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-2 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/d313c571a89743b1b7d88d1fb057f169
Autor:
Hagop Kantarjian, Nitin Jain, Koji Sasaki, Elias Jabbour, Fadi G. Haddad, Sanam Loghavi, Rashmi Kanagal-Shamanna, Jeffrey Jorgensen, Issa Khouri, Partow Kebriaei, Yesid Alvarado, Tapan M. Kadia, Shilpa Paul, Guillermo Garcia-Manero, Bouthaina Dabaja, Musa Yilmaz, Jovitta Jacob, Rebecca Garris, Susan O'Brien, Farhad Ravandi
Publikováno v:
Journal of hematology & oncology, vol 16, iss 1
Background Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential blinatumomab to low-intensity m
Autor:
Guillermo Garcia-Manero, Nicholas J. Short, Keyur P. Patel, Elias Jabbour, Mansour Alfayez, Tapan M. Kadia, Naval Daver, Koichi Takahashi, Ahmad S. Alotaibi, Hagop M. Kantarjian, Sherry Pierce, Musa Yilmaz, Jorge E. Cortes, Farhad Ravandi, Courtney D. DiNardo, Issa Ghayas, Guillermo Montalban-Bravo, Rita Assi, Marina Konopleva, Sanam Loghavi, Naveen Pemmaraju, Michael Andreeff, Rashmi Kanagal-Shamanna, Maro Ohanian, Gautam Borthakur
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45–55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of patients treated were prior FLT3
Autor:
Musa Yilmaz, Ghayas C. Issa, Farhad Ravandi, Kapil Saxena, Koji Sasaki, Naval Daver, Marina Konopleva, Hagop M. Kantarjian, Courtney D. DiNardo, Sherry Pierce, Elias Jabbour, Jorge E. Cortes, Abhishek Maiti, Nicholas J. Short, Kelly S. Chien, Tapan M. Kadia
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-10 (2021)
Background The natural course of untreated chronic myeloid leukemia (CML) is progression to an aggressive blast phase. Even in the current era of BCR-ABL1 tyrosine kinase inhibitors (TKIs), the outcomes of blast phase CML remain poor with no consensu
Autor:
Nicholas J. Short, Musa Yilmaz, Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Guillermo Garcia Manero, Sanam Loghavi, Hagop M. Kantarjian, Jorge E. Cortes, Rashmi Kanagal-Shamanna, Issa Ghayas, Sherry Pierce, Guillermo Montalban-Bravo, Ahmad S. Alotaibi, Farhad Ravandi, Mansour Alfayez, Rita Assi, Naveen Pemmaraju, Marina Konopleva, Michael Andreeff, Koichi Takahashi, Keyur P. Patel, Elias Jabbour, Gautam Borthakur, Maro Ohanian
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-2 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Autor:
Short, Nicholas J.1 (AUTHOR) nshort@mdanderson.org, Venugopal, Sangeetha1 (AUTHOR), Qiao, Wei2 (AUTHOR), Kadia, Tapan M.1 (AUTHOR), Ravandi, Farhad1 (AUTHOR), Macaron, Walid1 (AUTHOR), Dinardo, Courtney D.1 (AUTHOR), Daver, Naval1 (AUTHOR), Konopleva, Marina1 (AUTHOR), Borthakur, Gautam1 (AUTHOR), Shpall, Elizabeth J.3 (AUTHOR), Popat, Uday3 (AUTHOR), Champlin, Richard E.3 (AUTHOR), Mehta, Rohtesh3 (AUTHOR), Al-Atrash, Gheath3 (AUTHOR), Oran, Betul3 (AUTHOR), Jabbour, Elias1 (AUTHOR), Garcia-Manero, Guillermo1 (AUTHOR), Issa, Ghayas C.1 (AUTHOR), Montalban-Bravo, Guillermo1 (AUTHOR)
Publikováno v:
Journal of Hematology & Oncology. 1/29/2022, Vol. 15 Issue 1, p1-10. 10p.
Autor:
Yilmaz, Musa1 (AUTHOR), Alfayez, Mansour1 (AUTHOR), DiNardo, Courtney D.1 (AUTHOR), Borthakur, Gautam1 (AUTHOR), Kadia, Tapan M.1 (AUTHOR), Konopleva, Marina Y.1 (AUTHOR), Loghavi, Sanam2 (AUTHOR), Kanagal-Shamanna, Rashmi2 (AUTHOR), Patel, Keyur P.2 (AUTHOR), Jabbour, Elias J.1 (AUTHOR), Garcia‑Manero, Guillermo1 (AUTHOR), Pemmaraju, Naveen1 (AUTHOR), Pierce, Sherry A.1 (AUTHOR), Ghayas, Issa1 (AUTHOR), Short, Nicholas J.1 (AUTHOR), Montalban-Bravo, Guillermo1 (AUTHOR), Takahashi, Koichi1 (AUTHOR), Assi, Rita1 (AUTHOR), Alotaibi, Ahmad S.1 (AUTHOR), Ohanian, Maro1 (AUTHOR)
Publikováno v:
Journal of Hematology & Oncology. 2/23/2021, Vol. 14 Issue 1, p1-2. 2p.
Autor:
Yilmaz, Musa1 (AUTHOR), Alfayez, Mansour1 (AUTHOR), DiNardo, Courtney D.1 (AUTHOR), Borthakur, Gautam1 (AUTHOR), Kadia, Tapan M.1 (AUTHOR), Konopleva, Marina Y.1 (AUTHOR), Loghavi, Sanam2 (AUTHOR), Kanagal-Shamanna, Rashmi2 (AUTHOR), Patel, Keyur P.2 (AUTHOR), Jabbour, Elias J.1 (AUTHOR), Garcia-Manero, Guillermo1 (AUTHOR), Pemmaraju, Naveen1 (AUTHOR), Pierce, Sherry A.1 (AUTHOR), Ghayas, Issa1 (AUTHOR), Short, Nicholas J.1 (AUTHOR), Montalban-Bravo, Guillermo1 (AUTHOR), Takahashi, Koichi1 (AUTHOR), Assi, Rita1 (AUTHOR), Alotaibi, Ahmad S.1 (AUTHOR), Ohanian, Maro1 (AUTHOR)
Publikováno v:
Journal of Hematology & Oncology. 10/8/2020, Vol. 13 Issue 1, pN.PAG-N.PAG. 1p.